Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology

Statistically Significant Improvement in Key Cardiac Parameter in Patients Switched From Enzyme Replacement Therapies to Migalastat

CRANBURY, N.J. and PHILADELPHIA, Nov. 15, 2014  -- Amicus Therapeutics (FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat") for Fabry disease.

Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit

-Benefit observed across multiple endpoints in bevacizumab-naive patients-
-Clear signs of clinical activity in difficult to treat bevacizumab-refractory patients-

HAMPTON, N.J., Nov. 14, 2014  -- Celldex Therapeutics, Inc. (CLDX) today announced an interim update from the Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM). The ReACT results demonstrate clear signs of clinical activity in patients with recurrent glioblastoma, including groups both naive and refractory to bevacizumab (Avastin^(R)). The data were presented in a platform presentation by David A. Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Center and Associate Professor of Medicine, Harvard Medical School, and the lead investigator of the ReACT study, at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in conjunction with the 19th Annual Meeting of the Society for Neuro-Oncology (SNO). A webcast/conference call will be held at 5:00 pm ET today to discuss the results (details provided below).

FibroGen, Inc. Announces Pricing of Its Initial Public Offering

SAN FRANCISCO-- FibroGen, Inc. (FGEN), a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs, today announces the pricing of its initial public offering of 8,100,000 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the shares are being offered by FibroGen. FibroGen completed a 1-for-2.5 reverse stock split effective as of November 10, 2014. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "FGEN" on November 14, 2014. In addition, FibroGen has granted the underwriters a 30-day option to purchase up to an additional 1,215,000 shares of common stock from FibroGen at the initial public offering price. The offering is expected to close on November 19, 2014, subject to customary closing conditions.